ERNA Ernexa Therapeutics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 748592 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY755.9%
TTM net income YoY-105.6%
TTM EPS YoY-1,100.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin83.5%
Operating margin-2,693.1%
Net margin-7,652.7%
FCF margin-2,784.4%
EBITDA margin-2,648.8%
Returns
ROE-2,264.3%
ROA-163.7%
ROIC (approx.)—
Asset turnover0.02x
Leverage & solvency
Liabilities / assets67.7%
Debt / equity0.00x
Current ratio0.80x
Interest coverage2.09x
Cash quality & payout
Operating cash flow / net income0.36x
Accruals ratio-105.5%
Payout ratio—
Capex / revenue63.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | $582,000 |
| Cost of revenue | — | $96,000 |
| Gross profit | — | $486,000 |
| R&D expense | $4.16M | $4.60M |
| SG&A expense | $5.16M | $13.13M |
| Operating income | -$9.32M | -$15.67M |
| Interest expense | -$100,000 | -$6.80M |
| Pretax income | -$14.13M | -$44.51M |
| Income tax | -$45,000 | $30,000 |
| Net income | -$14.08M | -$44.54M |
| EBITDA | -$9.25M | -$15.54M |
| EPS (basic) | -2.24 | -48.96 |
| EPS (diluted) | -2.24 | -48.96 |
| Weighted avg. shares (diluted) | 6.31M | 910,000 |
| Balance sheet | ||
| Cash & equivalents | $1.88M | $1.73M |
| Current assets | $3.13M | $2.35M |
| PP&E, net | $94,000 | $85,000 |
| Goodwill | $2.04M | $2.04M |
| Total assets | $5.83M | $5.27M |
| Current liabilities | $3.11M | $2.94M |
| Total liabilities | $3.43M | $3.57M |
| Shareholders' equity | $2.40M | $1.70M |
| Shares outstanding | 314,000 | 3.43M |
| Cash flow statement | ||
| Operating cash flow | -$7.02M | -$15.84M |
| Capital expenditure | $37,000 | $369,000 |
| Free cash flow | -$7.05M | -$16.20M |
| Investing cash flow | -$37,000 | -$365,000 |
| Financing cash flow | $7.21M | $6.26M |
| Depreciation & amortization | $65,000 | $139,000 |
| Stock-based compensation | $1.50M | $1.52M |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.